198 related articles for article (PubMed ID: 22135726)
1. Intravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway.
Shen Q; Duan X; Feng W; Nguyen N; Lapus A; Brown RE; Chen L
Int J Clin Exp Pathol; 2011; 4(8):782-90. PubMed ID: 22135726
[TBL] [Abstract][Full Text] [Related]
2. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
3. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Gupta M; Ansell SM; Novak AJ; Kumar S; Kaufmann SH; Witzig TE
Blood; 2009 Oct; 114(14):2926-35. PubMed ID: 19641186
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like Growth Factor II mRNA-binding Protein 3 is a Highly Sensitive Marker for Intravascular Large B-cell Lymphoma: Immunohistochemical Analysis of 152 Pathology Specimens From 88 Patients.
Saka M; Fujimoto M; Mizoguchi K; Tsujimura M; Saeki M; Hirata M; Shibuya S; Odani K; Sakurai T; Yuba Y; Moriyoshi K; Nakajima N; Sumiyoshi S; Kono F; Ono K; Shirase T; Watanabe C; Yoshizawa A; Haga H
Am J Surg Pathol; 2024 Jun; 48(6):671-680. PubMed ID: 38497417
[TBL] [Abstract][Full Text] [Related]
6. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
[TBL] [Abstract][Full Text] [Related]
7. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
8. mTOR activity in AIDS-related diffuse large B-cell lymphoma.
Browne SH; Diaz-Perez JA; Preziosi M; King CC; Jones GA; Jain S; Sun X; Reid EG; VandenBerg S; Wang HY
PLoS One; 2017; 12(2):e0170771. PubMed ID: 28192480
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
10. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
Shen Q; Stanton ML; Feng W; Rodriguez ME; Ramondetta L; Chen L; Brown RE; Duan X
Int J Clin Exp Pathol; 2010 Nov; 4(1):13-21. PubMed ID: 21228924
[TBL] [Abstract][Full Text] [Related]
11. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
[TBL] [Abstract][Full Text] [Related]
14. Intravascular large B-cell lymphoma involving large blood vessels, three autopsy cases.
Sato S; Teshima S; Nakamura N; Ohtake T; Kikuchi J; Kishi H; Nomura K; Kurose N; Masaki Y; Tamaru JI
Pathol Int; 2019 Feb; 69(2):97-103. PubMed ID: 30672647
[TBL] [Abstract][Full Text] [Related]
15. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
16. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
Sebestyén A; Sticz TB; Márk A; Hajdu M; Timár B; Nemes K; Nagy N; Váradi Z; Kopper L
Mod Pathol; 2012 Dec; 25(12):1623-8. PubMed ID: 22899290
[TBL] [Abstract][Full Text] [Related]
17. Presentation and management of intravascular large B-cell lymphoma.
Shimada K; Kinoshita T; Naoe T; Nakamura S
Lancet Oncol; 2009 Sep; 10(9):895-902. PubMed ID: 19717091
[TBL] [Abstract][Full Text] [Related]
18. Kidney-limited intravascular large B cell lymphoma: a distinct variant of IVLBCL?
Kameoka Y; Takahashi N; Komatsuda A; Tagawa H; Hamai K; Hirokawa M; Wakui H; Ichinohasama R; Sawada KI
Int J Hematol; 2009 May; 89(4):533-537. PubMed ID: 19322627
[TBL] [Abstract][Full Text] [Related]
19. Dominant neurologic symptomatology in intravascular large B-cell lymphoma.
Kubisova K; Martanovic P; Sisovsky V; Tomleinova Z; Steno A; Janega P; Rychly B; Babal P
Bratisl Lek Listy; 2016; 117(6):308-11. PubMed ID: 27546361
[TBL] [Abstract][Full Text] [Related]
20. [Proposal of possible diagnostic strategy for intravascular large B-cell lymphoma--usefulness of biopsy from senile hemangioma].
Ishida M; Yoshii M; Yoshida T; Okabe H
Rinsho Byori; 2012 Mar; 60(3):201-5. PubMed ID: 22568081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
